Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 4,129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neck Neoplasms Clear all
Recruiting Phase 1 Interventional

Study of Treatment for HPV16+ ASC-US or LSIL

NCT03913117
View directory record Official record
Conditions
ASC-US, LSIL
Interventions
pNGVL4aCRTE6E7L2, TA-CIN
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Nov 15, 2026, 1:55 PM EST
Terminated Phase 1 Interventional

A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab

NCT02124850
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Motolimod, Cetuximab, Nivolumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2019 · Synced Nov 15, 2026, 1:55 PM EST
Terminated Not applicable Interventional

Stellate Ganglion Block in Head and Neck Cancer Surgery

NCT03714906
View directory record Official record
Conditions
Head and Neck Cancer, Pain, Postoperative
Interventions
Stellate ganglion block
Procedure
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Nov 15, 2026, 1:55 PM EST
Completed Phase 2 Interventional Results available

Study in Advanced Solid Tumors

NCT01099358
View directory record Official record
Conditions
Solid Tumor
Interventions
Cetuximab, Cisplatin, 5 - Fluorouracil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
5
States / cities
Fayetteville, Arkansas • Fairway, Kansas • Reno, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Nov 15, 2026, 1:55 PM EST
Completed Phase 1 Interventional

Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer

NCT00507858
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pemetrexed, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2011 · Synced Nov 15, 2026, 1:55 PM EST
Active, not recruiting Phase 2 Interventional

Induction Chemotherapy for Locally Advanced Esophageal Cancer

NCT03110926
View directory record Official record
Conditions
Esophageal Carcinoma
Interventions
mFOLFOX6, Chemoradiation
Drug · Combination Product
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Nov 15, 2026, 1:55 PM EST
Completed Phase 3 Interventional

Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix

NCT00003078
View directory record Official record
Conditions
Cervical Cancer
Interventions
cisplatin, fluorouracil, brachytherapy, radiation therapy
Drug · Radiation
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Nov 15, 2026, 1:55 PM EST
Active, not recruiting Phase 1 Interventional

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

NCT07118176
View directory record Official record
Conditions
Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Colorectal Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Lung Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Neoplasm of Unknown Primary, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Uterine Neoplasm, Neuroendocrine Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Penile Carcinoma, Pleural Carcinomatosis, Primary Peritoneal Carcinoma, Prostate Carcinoma, Salivary Gland Carcinoma, Sarcoma, Skin Carcinoma, Solitary Fibrous Tumor, Thymus Carcinoma, Thyroid Gland Carcinoma, Thyroid Gland Medullary Carcinoma, Urothelial Carcinoma, Vaginal Carcinoma
Interventions
Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46, Positron Emission Tomography
Procedure · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 15, 2026, 1:55 PM EST
Active, not recruiting Phase 2 Interventional

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

NCT04675333
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
evorpacept, pembrolizumab, Cisplatin/Carboplatin; 5FU
Drug
Lead sponsor
ALX Oncology Inc.
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
13
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Nov 15, 2026, 1:55 PM EST
Active, not recruiting Phase 1 Interventional

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

NCT06607185
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Nov 15, 2026, 1:55 PM EST
Recruiting Phase 4 Interventional

Intraoperative Methadone for the Management of Postoperative Pain in Patients With Head and Neck Cancers

NCT07857655
View directory record Official record
Conditions
Head and Neck Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Carcinoma
Interventions
Electronic Health Record Review, Fentanyl, Laryngoscopy, Methadone, Surgical Procedure, Survey Administration
Other · Drug · Device + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 89 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 15, 2026, 1:55 PM EST
Active, not recruiting Not applicable Interventional

Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx

NCT04667585
View directory record Official record
Conditions
Oropharynx Cancer
Interventions
De-escalated radiation dose, Standard radiation dose, 18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)-Computed Tomography (CT)
Radiation · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Nov 15, 2026, 1:55 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Imaging With a PET Agent for Detection of Cancers of the Head and Neck

NCT03631017
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
[18F]- PARPi, PET/CT Scans
Drug · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Nov 15, 2026, 1:55 PM EST
Completed Phase 2 Interventional Results available

Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors

NCT00515216
View directory record Official record
Conditions
Stomach Neoplasms, Esophageal Neoplasms
Interventions
5-fluorouracil, Oxaliplatin, Leucovorin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
4
States / cities
Birmingham, Alabama • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Nov 15, 2026, 1:55 PM EST
Completed Phase 1 Interventional

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors

NCT03811652
View directory record Official record
Conditions
Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC), Small Cell Lung Cancer (SCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
MEDI7247
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 101 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Huntersville, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Nov 15, 2026, 1:55 PM EST
Completed Phase 3 Interventional

Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer

NCT00090337
View directory record Official record
Conditions
Head and Neck Cancer, Pain
Interventions
acupuncture therapy, standard follow-up care
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Nov 15, 2026, 1:55 PM EST
Terminated Phase 1 Interventional

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

NCT04000529
View directory record Official record
Conditions
Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal SCC, Gastrointestinal Stromal Tumors, Colorectal Cancer
Interventions
TNO155, Spartalizumab, Ribociclib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Nov 15, 2026, 1:55 PM EST
Completed Phase 2 Interventional Results available

GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer

NCT01553851
View directory record Official record
Conditions
Neoplasms, Oral, Mouth Neoplasms
Interventions
GSK1120212
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 26, 2016 · Synced Nov 15, 2026, 1:55 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Message Framing Intervention for Increasing Parental Acceptance of Human Papillomavirus Vaccination

NCT03856437
View directory record Official record
Conditions
Cervical Cancer, Anal Cancer, Penile Cancer
Interventions
HPV vaccination messages
Behavioral
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years to 99 Years
Enrollment
1,170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Nov 15, 2026, 1:55 PM EST
Active, not recruiting Phase 2 Interventional Results available

Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion

NCT02581137
View directory record Official record
Conditions
Erythroplakia, Hyperplasia, Oral Cavity Carcinoma, Oral Leukoplakia
Interventions
Laboratory Biomarker Analysis, Metformin Hydrochloride
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
San Diego, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 13, 2026 · Synced Nov 15, 2026, 1:55 PM EST
Not listed Phase 1 Interventional

Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers

NCT02970539
View directory record Official record
Conditions
Gastric Cancer, Esophageal Cancer, Gastro-esophageal Cancer
Interventions
Oraxol, Ramucirumab
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Nov 15, 2026, 1:55 PM EST
Completed Phase 2 Interventional Results available

A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

NCT02657551
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Regorafenib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Nov 15, 2026, 1:55 PM EST
Completed Phase 2 Interventional Results available

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

NCT04326257
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Nivolumab+Relatlimab, Nivolumab+Ipilimumab
Drug
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Nov 15, 2026, 1:55 PM EST
Completed No phase listed Observational

Utility and Cost-effectiveness of Microscopic Examination of the Neck Dissection.

NCT03237195
View directory record Official record
Conditions
Metastasis
Interventions
additional soft tissue in neck dissections
Other
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
Not listed
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Nov 15, 2026, 1:55 PM EST